Hyperkalemia-Related RAASi Reduction and Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining RAASi.

IF 3.2 Q1 UROLOGY & NEPHROLOGY
Maria K Svensson, Michael Fischereder, Paul R Kalra, Ignacio José Sánchez Lázaro, Eva Lesén, Stefan Franzén, Alaster Allum, Thomas Cars, Nils Kossack, Philipp Breitbart, David Arroyo
{"title":"Hyperkalemia-Related RAASi Reduction and Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining RAASi.","authors":"Maria K Svensson, Michael Fischereder, Paul R Kalra, Ignacio José Sánchez Lázaro, Eva Lesén, Stefan Franzén, Alaster Allum, Thomas Cars, Nils Kossack, Philipp Breitbart, David Arroyo","doi":"10.34067/KID.0000000000000561","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Renin-angiotensin-aldosterone system inhibitor (RAASi) therapy provides cardiorenal protection but is often down-titrated or discontinued following a hyperkalemia episode. This observational study describes the extent of hyperkalemia-related RAASi reduction in patients with chronic kidney disease (CKD) and/or heart failure (HF), and estimates the number needed to treat (NNT) to avoid a first hospitalization if RAASi had been maintained at the prior dose.</p><p><strong>Methods: </strong>Healthcare registers and claims data from Germany, Spain, Sweden, and the UK were used to identify non-dialysis patients with CKD and/or HF who had a hyperkalemia episode while on RAASi. Patients whose RAASi therapy was reduced (down-titrated/discontinued) after the hyperkalemia episode were propensity score (PS)-matched to those with maintained RAASi, and their risks of a hospitalization within 6 months were estimated using the Kaplan-Meier method. Based on the absolute difference in this 6-month risk, the NNT framework was applied to estimate the number of patients who needed to have maintained instead of reduced their RAASi to avoid a first hospitalization during this period.</p><p><strong>Results: </strong>Overall, 40,059 patients from Germany, Spain, Sweden, and the UK were included. Presence of CKD at baseline was similar across countries (72%-92%), while HF was less common in Spain (18%) versus other countries (32%-71%). After the hyperkalemia episode, RAASi was reduced in 25%-57% of patients. Following PS matching, the 6-month risk of hospitalization was consistently higher in those with reduced versus maintained RAASi; the absolute risk difference ranged from 2.7% to 7.3%. Applying the NNT framework, these data suggest that a first hospitalization within 6 months could potentially have been avoided if 25 patients had maintained instead of reduced their RAASi.</p><p><strong>Conclusions: </strong>Our findings suggest a potential for avoiding a first hospitalization, even within a short time frame, by increasing adherence to guidelines to maintain instead of reduce RAASi after a hyperkalemia episode.</p>","PeriodicalId":17882,"journal":{"name":"Kidney360","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney360","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34067/KID.0000000000000561","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Renin-angiotensin-aldosterone system inhibitor (RAASi) therapy provides cardiorenal protection but is often down-titrated or discontinued following a hyperkalemia episode. This observational study describes the extent of hyperkalemia-related RAASi reduction in patients with chronic kidney disease (CKD) and/or heart failure (HF), and estimates the number needed to treat (NNT) to avoid a first hospitalization if RAASi had been maintained at the prior dose.

Methods: Healthcare registers and claims data from Germany, Spain, Sweden, and the UK were used to identify non-dialysis patients with CKD and/or HF who had a hyperkalemia episode while on RAASi. Patients whose RAASi therapy was reduced (down-titrated/discontinued) after the hyperkalemia episode were propensity score (PS)-matched to those with maintained RAASi, and their risks of a hospitalization within 6 months were estimated using the Kaplan-Meier method. Based on the absolute difference in this 6-month risk, the NNT framework was applied to estimate the number of patients who needed to have maintained instead of reduced their RAASi to avoid a first hospitalization during this period.

Results: Overall, 40,059 patients from Germany, Spain, Sweden, and the UK were included. Presence of CKD at baseline was similar across countries (72%-92%), while HF was less common in Spain (18%) versus other countries (32%-71%). After the hyperkalemia episode, RAASi was reduced in 25%-57% of patients. Following PS matching, the 6-month risk of hospitalization was consistently higher in those with reduced versus maintained RAASi; the absolute risk difference ranged from 2.7% to 7.3%. Applying the NNT framework, these data suggest that a first hospitalization within 6 months could potentially have been avoided if 25 patients had maintained instead of reduced their RAASi.

Conclusions: Our findings suggest a potential for avoiding a first hospitalization, even within a short time frame, by increasing adherence to guidelines to maintain instead of reduce RAASi after a hyperkalemia episode.

与高钾血症相关的 RAASi 降低率以及通过维持 RAASi 避免首次住院的估计治疗需求人数。
背景:肾素-血管紧张素-醛固酮系统抑制剂(RAASi)治疗可保护心肾功能,但通常在高钾血症发作后会减量或停药。本观察性研究描述了慢性肾脏病(CKD)和/或心力衰竭(HF)患者中与高钾血症相关的 RAASi 降量程度,并估算了如果 RAASi 保持之前的剂量,为避免首次住院治疗所需的治疗人数(NNT)。方法:利用德国、西班牙、瑞典和英国的医疗登记和理赔数据来识别在服用 RAASi 期间出现高钾血症的非透析 CKD 和/或 HF 患者。高钾血症发作后,RAASi 治疗减少(降量/停药)的患者与维持 RAASi 治疗的患者进行倾向评分(PS)匹配,并使用 Kaplan-Meier 法估算他们在 6 个月内住院的风险。根据 6 个月内风险的绝对差异,采用 NNT 框架估算出在此期间需要维持 RAASi 而不是降低 RAASi 才能避免首次住院的患者人数:总共纳入了来自德国、西班牙、瑞典和英国的 40,059 名患者。各国基线时存在慢性肾功能衰竭的比例相似(72%-92%),而西班牙(18%)与其他国家(32%-71%)相比,高血压的发病率较低。高钾血症发作后,25%-57% 的患者 RAASi 下降。经过 PS 匹配后,RAASi 下降的患者与 RAASi 保持不变的患者的 6 个月住院风险一直较高;绝对风险差异从 2.7% 到 7.3% 不等。应用 NNT 框架,这些数据表明,如果 25 名患者保持而不是降低 RAASi,就有可能避免 6 个月内的首次住院:我们的研究结果表明,在高钾血症发作后,通过加强对指南的遵守,维持而不是降低 RAASi,有可能避免首次住院,即使是在很短的时间内。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Kidney360
Kidney360 UROLOGY & NEPHROLOGY-
CiteScore
3.90
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信